Phase 4 N=80 Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots
Hyperpigmentation
Primary: Change in Hyperpigmentation of the Face — .8; .3; .45; .56 units on a scale — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=48 Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
HIV Infections · AIDS · Dyslipidemia
Primary: Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group. — -34; 40 mg/dl — p=0.01
Phase 4 N=160 Management of Postoperative Pain After Total Knee Replacement.
Postoperative Pain · Knee Replacement Arthroplasty
Primary: Post-Operative Pain — 2.9; 3.0 units on a scale — p=0.76
Phase 4 N=64 Tissue Glue (Cyanoacrylate) Versus Conventional Suture in Kidney Donors
Skin Closure of Surgical Incisions by Tissue Glue vs Suture
Primary: Wound Healing by Numerical Scales for Rubor Postoperative Day 2. — 0.516; 0.984 units on a scale
Phase 4 N=949 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Angina Pectoris · Coronary Artery Disease · Type 2 Diabetes Mellitus
Primary: Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment — 5.2; 4.5 angina attacks per week — p=0.008
Phase 4 N=436 Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome
Primary: Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall Score — 13.8; 8.4 units on a scale — p=0.0008
Phase 4 N=12 Eszopiclone Treatment & Cortisol Responsivity
Insomnia
Primary: Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug) — 108.98 nmol/L
Phase 4 N=40 A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
Rheumatoid Arthritis
Primary: Percentage of Participants With An American College of Rheumatology 20 Percent (%) Improvement Criteria (ACR20) Response at Week 24 — 47.5 percentage of participants
Phase 4 N=160 An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining
Oral Hygiene
Primary: Modified Lobene Stain Index (MLSI) at Week 6 — 0.97; 1.22 Score on a Scale — p=0.1313
Phase 4 N=77 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Parkinson's Disease
Primary: Percentage of Participants With Reduction in Adverse Events — 94; 86; 73; 84 percentage of participants
Phase 4 N=49 Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
Diabetes Mellitus
Primary: Diabetes Treatment Satisfaction Questionnaire: Status (DTSQs) Score — 28.2; 31.5; 32.2; 34.2 units on a scale
Phase 4 N=456 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
Type 1 Diabetes Mellitus
Primary: Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c) — -0.14; -0.18 percentage of HbA1c — p=0.4516
Phase 4 N=150 Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
Glaucoma
Primary: Ocular Tolerance — 65; 34 participants — p=< 0.001
Phase 4 N=40 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change in Best Corrected Visual Acuity (BCVA) Measured Using Early Treatment of Diabetic Retinopathy Study (ETDRS) Methodology at Month 12 Compared to Baseline — 4.9…
Phase 4 N=1,384 Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules
Rotavirus Infection
Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants